Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October

NEWTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Alexey Margolin, Ph.D., Allena’s Chief Executive Officer, will present a corporate update at two investor conferences in October:

Ladenburg Thalmann 2018 Healthcare Conference
Date: Tuesday, October 2, 2018
Time: 10:00 a.m. ET
Location: New York, NY

2018 Cantor Global Healthcare Conference
Date: Wednesday, October 3, 2018
Time: 4:00 p.m. ET
Location: New York, NY

Live audio webcasts of both presentations will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]

You May Also Be Interested In

• Crypto News: Pepeto Announces $10.917M Raised Following the Shiba Inu Success While Cardano Price Prediction Turns Bullish
• San Joaquin Valley College Hosts Skilled Trades Night
• Meeting Nutrition and Sustainability Needs With Hybrid Protein Products